We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood Test Monitors DNA Fragments for Melanoma Metastases

By LabMedica International staff writers
Posted on 25 Jan 2016
Print article
Image: Clinical features of local recurrences that are defined as the reappearance of melanoma in or contiguous with an excision scar or graft and bearing an in situ component (Photo courtesy of Dr. Paola Savoia).
Image: Clinical features of local recurrences that are defined as the reappearance of melanoma in or contiguous with an excision scar or graft and bearing an in situ component (Photo courtesy of Dr. Paola Savoia).
A blood test which monitors blood levels of DNA fragments from dead cancer cells does a superior job than the current standard test at tracking the severity and potential spread of metastatic melanoma.

The standard test, in widespread use for decades to inform treatment decisions, measures blood levels of the enzyme lactate dehydrogenase (LDH). Levels of the enzyme tend to spike during aggressive tumor growth, but are also known to rise as part of other diseases and biological functions.

Scientists at the New York University School of Medicine (NY, USA) and their colleagues looks at levels of circulating tumor DNA, or ctDNA, released into the blood when tumor cells die and break apart to spill their contents. They studied 31 patients with inoperable metastatic melanoma, which took three years to complete. All had one of the two most common genetic mutations linked to the frequently fatal skin cancer, B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) or Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS). All had ctDNA and LDH blood tests performed after therapy, and most before treatment.. Normal blood levels of ctDNA were statistically determined by averaging results from 30 people who did not have melanoma.

The ctDNA levels were determined using droplet digital PCR (ddPCR) assays. Among patients with samples available prior to treatment initiation ctDNA and LDH levels were elevated in 12/15 (80%) and 6/20 (30%) patients respectively. In patients with Response Evaluation Criteria In Solid Tumors (RECIST) scores greater than 5 cm prior to treatment initiation, ctDNA levels were elevated in 5/7 (71%) patients compared to LDH which was elevated in 1/13 (8%) patients. In addition, ctDNA levels were elevated in 13/16 (81%) instances of non-RECIST disease progression, including 10/12 (83%) instances of new brain metastases. In comparison LDH was elevated 8/16 (50%) instances of non-RECIST disease progression, including 6/12 (50%) instances of new brain metastases.

David Polsky, MD, PhD, the senior author of the study, said, “Our study results show that circulating tumor DNA is a superior blood test for evaluating and tracking progression of metastatic melanoma. A reliable blood test for tracking potential disease progression is preferred because blood tests offer feedback on what is happening throughout the body, while scans may not always visualize all parts of the body.” The study was published in the January, 2016 edition of the journal Molecular Oncology.

Related Links:

New York University School of Medicine 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.